Ogivri 150 mg powder for concentrate for solution for infusion, TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets
IC 2024-01
Phase 2 small_molecule active
Quick answer
Ogivri 150 mg powder for concentrate for solution for infusion, TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets for HER3-mutant and HER2-not amplified metastatic breast cancer is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- HER3-mutant and HER2-not amplified metastatic breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active